Depression, anxiety prevalent among hemophilia patients: Study
About a quarter (24.4%) of men with hemophilia A and B seen at a clinic in Turkey met…
Articles by Lindsey Shapiro, PhD
Severe bleeds seen in small number of young patients on Hemlibra
A small percentage of young people with hemophilia A who are on preventive treatment with Hemlibra (emicizumab) experience…
BioMarin: Roctavian for Hem A likely to patients by end of summer
The approval by the U.S. Food and Drug Administration (FDA) of BioMarin Pharmaceutical’s Roctavian (valoctocogene roxaparvovec-rvox) late last month…
HFA launches ‘clinical trial finder’ for patients with bleeding disorders
The Hemophilia Federation of America (HFA) is now offering a “clinical trial finder” to help people with hemophilia…
Stimulating vagus nerve controls bleeding in hemophilia mouse model
Electrically stimulating the vagus nerve — the main set of nerve fibers that control involuntary bodily functions — significantly reduced…
Marstacimab seen to lower bleed rates in hemophilia in Phase 3 trial
Weekly treatment with the experimental therapy marstacimab (PF-06741086) was found to significantly reduce bleed rates for adult and adolescent…
Rebinyn cost-effective relative to other FIX therapies, study finds
Switching to Rebinyn (nonacog beta pegol) from other standard or extended half-life replacement therapies led to “robust” reductions in…
Third of hemophilia patients in study perceived declines in function
About one-third of moderate-to-severely affected people with hemophilia perceived declines in their daily functional abilities over a period of…
Phase 2 trials of SerpinPC to begin dosing this year
SerpinPC, an investigational treatment that Centessa Pharmaceuticals is developing for hemophilia, will advance to interventional Phase 2 clinical…
Chronic ankle pain in hemophilia significantly affects quality of life
People with moderate-to-severe hemophilia and ankle joint disease reported significant impairments in life quality and foot and ankle function,…